ACER - Acer Therapeutics Inc Stock Price, Fair Value and News

0.66USD Market Closed

Market Summary

USD0.66

Market Closed

ACER Stock Price

View Fullscreen

ACER RSI Chart

ACER Valuation

Market Cap

16.1M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

22.06

Price/Free Cashflow

-0.43

ACER Price/Sales (Trailing)

ACER Profitability

Return on Equity

-36.7%

Return on Assets

-346.28%

Free Cashflow Yield

-231.57%

ACER Fundamentals

ACER Revenue

Revenue (TTM)

731.8K

ACER Earnings

Earnings (TTM)

-48.5M

Earnings Growth (Yr)

-194.22%

Earnings Growth (Qtr)

-82.08%

Breaking Down ACER Revenue

Last 7 days

-8.0%

Last 30 days

5.3%

Last 90 days

10.0%

Trailing 12 Months

-35.0%

How does ACER drawdown profile look like?

ACER Financial Health

Current Ratio

0.1

Debt/Equity

0.02

Debt/Cashflow

-11.68

ACER Investor Care

Shares Dilution (1Y)

49.41%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	731.8K	0
2021	3.1M	2.4M	1.6M	1.3M
2016	2.9M	2.9M	2.9M	2.9M
2015	1.3M	1.7M	2.1M	2.6M
2014	1.4M	1.4M	1.3M	1.3M
2013	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Acer Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 17, 2023	davis jefferson e	back to issuer	-	-	-71,645	chief business officer
Nov 17, 2023	schelling chris	back to issuer	-	-	-2,712,530	president and ceo
Nov 17, 2023	palmin harry s	back to issuer	-	-	-125,000	chief financial officer
Nov 17, 2023	joseph donald	back to issuer	-	-	-14,285	see remarks
Nov 17, 2023	dunn john michael	back to issuer	-	-	-27,380	-
Nov 17, 2023	aselage steve	back to issuer	-	-	-483,741	-
Nov 29, 2022	aselage steve	bought	500,000	1.22	409,836	-
Nov 29, 2022	schelling chris	bought	1,000,000	1.22	819,672	president & ceo
Dec 10, 2021	aselage steve	bought	16,287	2.04	7,984	-
Dec 09, 2021	aselage steve	bought	4,334	2.15	2,016	-

Which funds bought or sold ACER recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Blue Trust, Inc.	sold off	-100	-1,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-386,387	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-50,000	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-748,454	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-43,786	-	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-2,611	-	-%
Feb 14, 2024	Tudor Investment Corp Et Al	sold off	-100	-755,538	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-21,624	-	-%
Feb 14, 2024	CSS LLC/IL	sold off	-100	-9,256	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%

Are Funds Buying or Selling ACER?

Are funds buying ACER calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACER

No. of Funds

Unveiling Acer Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 30, 2023	tvm life science ventures vi lp	1.1%	248,756	SC 13D/A
Feb 14, 2023	nantahala capital management, llc	7.5%	1,226,191	SC 13G/A
Dec 02, 2022	schelling chris	16.0%	2,858,995	SC 13D/A
Feb 14, 2022	nantahala capital management, llc	6.3%	901,290	SC 13G/A
Feb 12, 2021	nantahala capital management, llc	8.1%	989,755	SC 13G/A
Aug 06, 2020	hirschman orin	8.5%	982,446	SC 13G/A
Aug 03, 2020	schelling chris	17.3%	1,951,369	SC 13D/A
May 19, 2020	hirschman orin	5.4%	552,040	SC 13G
Feb 13, 2020	vivo opportunity, llc	0%	0	SC 13G/A
Feb 12, 2020	nantahala capital management, llc	9.8%	990,655	SC 13G/A

Peers (Alternatives to Acer Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Acer Therapeutics Inc News

Latest updates

Acer Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2021Q4	2021Q3	2021Q2	2021Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1
Revenue	3.3%	372	360	-	-	900	726	726	726	726	726	726	726	377	308	308	308	349	349	349	349	220
Costs and Expenses	-	13,250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-100.0%	-	4,780	3,279	3,630	5,520	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	52.6%	4,691	3,074	1,843	2,269	3,514	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-10.7%	1,522	1,705	1,435	1,361	2,006	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	613*	-	414*	108*	678.50*	2.00	2.00	731*	1.00	2.00	4.00	-	9*	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-233.2%	-14,731	-4,420	-3,273	-3,069	-4,611	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-443.0%	-66.26*	-12.20*	-5.92*	-6.83*	-7.76*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-899.8%	-14,404	-1,440	-7,976	6,228	3,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-4.4%	14.00	15.00	16.00	12.00	15.00	23.00	31.00	36.00	33.00	40.00	45.00	15.00	15.00	15.00	16.00	21.00	26.00	33.00	41.00	51.00	55.00
Current Assets	-9.1%	6.00	7.00	8.00	4.00	7.00	15.00	23.00	28.00	25.00	32.00	36.00	6.00	7.00	6.00	8.00	13.00	17.00	24.00	33.00	43.00	47.00
Cash Equivalents	-62.5%	1.00	2.00	6.00	2.00	6.00	14.00	21.00	13.00	14.00	22.00	16.00	6.00	6.00	6.00	7.00	12.00	16.00	23.00	32.00	42.00	46.00
Inventory	0%	5.00	5.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-24.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Liabilities	28.9%	62.00	48.00	42.00	28.00	28.00	32.00	42.00	38.00	30.00	35.00	37.00	6.00	5.00	4.00	2.00	3.00	3.00	5.00	3.00	6.00	2.00
Current Liabilities	42.0%	62.00	43.00	38.00	19.00	21.00	17.00	28.00	29.00	30.00	35.00	32.00	6.00	4.00	3.00	2.00	3.00	2.00	5.00	3.00	6.00	-
Shareholder's Equity	-	-	-	-	-	-	-	-	-	2.00	5.00	7.00	8.00	11.00	11.00	14.00	18.00	23.00	28.00	38.00	45.00	53.00
Retained Earnings	-8.9%	-179	-165	-157	-140	-131	-126	-123	-114	-110	-106	-103	-99.14	-92.90	-86.97	-81.20	-76.25	-71.09	-65.84	-54.80	-46.83	-38.34
Additional Paid-In Capital	0.2%	132	132	131	124	119	118	114	113	112	112	111	107	103	98.00	95.00	95.00	94.00	93.00	93.00	92.00	91.00
Shares Outstanding	0%	24.00	24.00	23.00	20.00	15.00	15.00	14.00	14.00	14.00	14.00	14.00	13.00	12.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	20.00	-	-	-	35.00	-	-	-	21.00	-	-	-	22.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-162.8%	-14,404	-5,482	-9,017	-8,346	-9,053	-9,886	-3,013	-1,385	-7,957	6,238	3,005	-3,900	-4,400	-3,629	-5,070	-3,991	-7,375	-8,389	-9,750	-4,590	-4,750
Share Based Compensation	-10.5%	233	260	286	446	460	461	474	533	600	595	559	466	487	604	667	662	564	715	672	387	353
Cashflow From Investing	-	-	-	-3.07	-135	-4.90	-2.00	-28.93	-20.49	-19.24	-9.90	-5.32	-8.67	-	-	-	-52.89	9.00	-46.02	-88.94	-10.70	-69.80
Cashflow From Financing	1881.0%	13,424	678	13,072	4,385	1,001	3,524	11,132	-	-	-	7,139	3,493	4,726	-	-	-	-	-	-	87.00	42,662

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACER Income Statement

2023-09-30

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Condensed Statements of Operations - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Product revenue, net	$ 371,790		$ 371,790
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember		us-gaap:ProductMember
Operating costs and expenses :
Cost of product revenue	$ 83,805		$ 83,805
Payments to collaboration partner	6,952,802		6,952,802
Research and development (net of collaboration funding of $0 and $2,178,078 in the three months ended September 30, 2023 and 2022, respectively, and of $1,318,482 and $6,826,080 in the nine months ended September 30, 2023 and 2022, respectively)	1,522,161	$ 2,681,680	5,383,998	$ 9,280,092
Selling, general and administrative (net of collaboration funding of $0 and $1,432,889 in the three months ended September 30, 2023 and 2022, respectively, and of $2,547,291 and $7,062,766 in the nine months ended September 30, 2023 and 2022, respectively)	4,690,960	2,557,370	10,112,902	10,071,044
Total operating costs expenses	13,249,728	5,239,050	22,533,507	19,351,136
Loss from operations	(12,877,938)	(5,239,050)	(22,161,717)	(19,351,136)
Other income (expense), net:
Costs of debt issuance		(122,400)	(577,225)	(1,490,594)
Loss on extinguishment of debt			(8,541,494)
Changes in fair value of debt instruments (loss) gain	(1,722,496)	324,550	(6,740,719)	4,091,610
Interest and other (expense) income, net	(133,157)	19,431	(1,059,304)	(122,641)
Foreign currency transaction gain (loss)	2,324	10,524	(22,234)	19,776
Total other (expense) income, net	(1,853,329)	232,105	(16,940,976)	2,498,151
Net loss	$ (14,731,267)	$ (5,006,945)	$ (39,102,693)	$ (16,852,985)
Net loss per share - basic	$ (0.60)	$ (0.31)	$ (1.68)	$ (1.11)
Weighted average common shares outstanding - basic	24,463,726	16,089,019	23,254,253	15,230,839
Net loss per share - diluted	$ (0.60)	$ (0.31)	$ (1.68)	$ (1.13)
Weighted average common shares outstanding - diluted	24,463,726	16,089,019	23,254,253	17,085,784

ACER Balance Sheet

2023-09-30

Condensed Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 594,659	$ 2,329,218
Inventory	5,202,597
Prepaid expenses	328,918	759,292
Deferred financing costs		408,000
Other current assets	14,638	20,188
Total current assets	6,140,812	3,516,698
Property and equipment, net	40,976	214,578
Other assets:
Goodwill	7,647,267	7,647,267
Other non-current assets	173,010	245,683
Total assets	14,002,065	11,624,226
Current liabilities:
Accounts payable	7,009,066	3,813,280
Accrued expenses	5,066,549	3,657,394
Deferred collaboration funding, current		8,412,971
Accrued payment to collaboration partner	1,500,000
Schelling Promissory Note payable to an officer	1,016,766
Other current liabilities	743,856	741,425
Convertible note payable, current, at fair value	14,635,200
Term Loans payable, current, at fair value	18,152,344	2,326,630
Zevra bridge loan payable	13,546,557
Total current liabilities	61,670,338	18,951,700
Term Loans payable, non-current, at fair value		3,240,601
Convertible note payable, at fair value		6,047,532
Other non-current liabilities	76,689	145,665
Total liabilities	61,747,027	28,385,498
Commitments and Contingencies (Note 9)
Stockholders’ deficit:
Preferred stock, $0.0001 par value; authorized 10,000,000 shares; none issued and outstanding
Common stock, $0.0001 par value; authorized 150,000,000 shares; 24,463,726 and 19,624,280 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	2,446	1,962
Additional paid-in capital	132,102,554	123,984,035
Accumulated deficit	(179,849,962)	(140,747,269)
Total stockholders’ deficit	(47,744,962)	(16,761,272)
Total liabilities and stockholders’ deficit	$ 14,002,065	$ 11,624,226

About Acer Therapeutics Inc

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

CEO	Mr. Christopher Schelling
WEBSITE	acertx.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Acer Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Acer Therapeutics Inc? What does ACER stand for in stocks?

ACER is the stock ticker symbol of Acer Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acer Therapeutics Inc (ACER)?

As of Mon Nov 20 2023, market cap of Acer Therapeutics Inc is 16.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACER stock?

You can check ACER's fair value in chart for subscribers.

What is the fair value of ACER stock?

You can check ACER's fair value in chart for subscribers. The fair value of Acer Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acer Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACER so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acer Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACER is over valued or under valued. Whether Acer Therapeutics Inc is cheap or expensive depends on the assumptions which impact Acer Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACER.

What is Acer Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 20 2023, ACER's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 22.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Acer Therapeutics Inc's stock?

In the past 10 years, Acer Therapeutics Inc has provided -0.421 (multiply by 100 for percentage) rate of return.